

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

DIETRICH, et al.

Serial No.: 10/505,138

Filed: August 19, 2004



Group Art: 1615

Examiner: SILVERMAN, E.

For: **ORAL DOSAGE FORM CONTAINING A PDE 4 INHIBITOR AS AN ACTIVE INGREDIENT AND POLYVINYLPIRROLIDON AS EXCIPIENT**

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

An Information Disclosure Statement is submitted herewith pursuant to 37 C.F.R. § 1.97-1.98. Please note the following particulars:

[NOTE: One only of items a, b, c, and d must be checked.]

- [] a. The enclosed statement is being filed within three months of the filing date of a national application, or within three months of the date of entry into the national stage as set forth in 37 C.F.R. § 1.491 in an international application, or before the mailing date of a first Office Action on the merits, whichever event occurs last.
- [] b. The enclosed statement is being filed after a first action on the merits but before the mailing date of a final action under 37 C.F.R. § 1.113, or a notice of allowance under 37 C.F.R. § 1.311.

The enclosed statement is accompanied by [check one]:

- [] i. a certification in part (e) below as specified in 37 C.F.R. § 1.97(e), or
- [] ii. a check in the amount required by 37 C.F.R. § 1.17(p).

- [**XX**] c. The enclosed statement is being filed after the mailing date of a final action under 37 C.F.R. § 1.113, or a notice of allowance under 37 C.F.R. § 1.311, but before payment of the issue fee.
[**XX**] Certification report(e) below; and
[**XX**] a check in the amount as required by § 1.17(p).

- [] d. The enclosed statement is being filed pursuant to 37 C.F.R. § 1.97(i), for placement in the file.

- [] e. Certification [Check one] [Certification is required only if box (b) (i) or box (c) is checked.]

- [] I hereby certify that each item of information contained in the enclosed Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement,
- or
- [**XX**] I hereby certify that no item of information in the enclosed Information Disclosure Statement herewith was cited in a communication from a foreign patent office in a counterpart foreign application, or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.
- or
- [] Appropriate certification is attached.
- [] f. If no check is enclosed and a fee is due in connection with this communication or if the check enclosed is insufficient, the Commissioner is authorized to charge any fee or additional fee due in connection with this communication to Deposit Account No. 14-0112.
- [**X**] g. Copies of the documents are attached herewith with a completed Form PTO-1449.
- And/or
- [] h. Copies of the documents are not attached as allowed under 1.98(d)(1)(2). The earlier application is identified as:
Or Copies of US Patents/Publications not attached as allowed in Official Gazette Aug. 5, 2003/ Vol. 1273, no. 1.


The Examiner is respectfully requested to cite the documents listed on the attached Form PTO-1449 in the next Office Action. In so doing, the Examiner is respectfully requested to initial in the space adjacent to the listing of each document on the Form PTO-1449, and return a copy of the initialed Form PTO-1449 with the next communication to Applicants, to confirm that these documents have been considered by the Examiner and made of record in this application.



If the Examiner has any questions or wishes to discuss this application, kindly telephone the undersigned at the below-listed number.

Date: June 1, 2006

NATH & ASSOCIATES PLLC
112 South West Street
Alexandria, VA 22314

Respectfully submitted,
NATH & ASSOCIATES PLLC


Gary M. Nath
Registration No. 26,965
Joshua B. Goldberg
Registration No. 44,126
Sheldon M. McGee
Registration No. 50,454
Customer No. 34375

 	Atty Docket 26230	Serial No. 10/505,138
	Applicant DIETRICH, et al.	
	Filing Date 8/19/2004	Group Art Unit 1615

INFORMATION DISCLOSURE CITATION

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Issue Date	Name	Class	Sub-Class	Filing Date
	AA					
	AB					
	AC					
	AD					
	AE					
	AF					
	AG					
	AH					
	AI					
	AJ					
	AK					

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Sub-Class	Translation
	AL					
	AM					
	AN					
	AO					
	AP					
	AR					

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AS	Hatzelmann, et al., "Anti-inflammatory and Immunomodulatory Potential of the Novel PDE4 Inhibitor Roflumilast in Vitro", <u>Jour. Pharm. Exp. Ther.</u> , Vol. 297, No. 1, pp. 267-279. (2000).
AT	
AU	

Examiner

Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP ' 609.
 Draw line through citation if not in conformance and not considered.
 Include copy of this form with next communication to Applicant.